Drug profile · INN
nilotinib tartrate
DANZITEN
nilotinib tartrate (DANZITEN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — nilotinib tartrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
nilotinib tartrate (DANZITEN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Frequently asked questions
What is nilotinib tartrate?
nilotinib tartrate (DANZITEN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nilotinib tartrate?
DANZITEN is a marketed brand name for nilotinib tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nilotinib tartrate?
nilotinib tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.